Treatment of Peripheral Precocious Puberty

Area of Science:

• Pediatric Endocrinology
• Genetics
• Reproductive Medicine

Background:

• Peripheral precocious puberty (PPP) presents with diverse etiologies and clinical manifestations due to excess androgens, estrogens, or both.
• Management aims to halt pubertal progression, normalize sex steroid levels, and preserve adult height potential.

Purpose of the Study:

• To review the etiologies, clinical presentations, and therapeutic approaches for peripheral precocious puberty (PPP).
• To specifically examine McCune-Albright syndrome (MAS) and familial male-limited precocious puberty (FMPP) as rare causes of PPP.

Main Methods:

• Literature review of studies investigating peripheral precocious puberty (PPP), focusing on McCune-Albright syndrome (MAS) and familial male-limited precocious puberty (FMPP).
• Analysis of therapeutic strategies and their reported success rates for these specific conditions.

Main Results:

• McCune-Albright syndrome (MAS) and familial male-limited precocious puberty (FMPP) stem from specific genetic mutations (GNAS1 and LH receptor, respectively).
• Therapeutic outcomes for FMPP are more established, with several successful options identified.
• Optimal treatment for MAS-induced precocious puberty in girls remains an area requiring further research.

Conclusions:

• Peripheral precocious puberty (PPP) requires tailored management based on etiology.
• Familial male-limited precocious puberty (FMPP) has viable treatment options.
• Further research is needed to define the best therapeutic strategies for McCune-Albright syndrome (MAS).